Zoetis Inc (NYSE:ZTS) has received a consensus rating of “Buy” from the sixteen analysts that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $124.00.
A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price objective (up previously from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. SunTrust Banks boosted their price objective on Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday, August 13th. Barclays boosted their price objective on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $111.00 to $120.00 in a research report on Monday, July 1st. They noted that the move was a valuation call.
ZTS stock traded up $1.10 during midday trading on Friday, reaching $125.37. 138,474 shares of the stock were exchanged, compared to its average volume of 2,059,244. The stock has a market capitalization of $59.97 billion, a PE ratio of 40.12, a P/E/G ratio of 3.09 and a beta of 0.87. Zoetis has a 52 week low of $78.90 and a 52 week high of $130.08. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. The company has a fifty day moving average price of $123.64 and a 200 day moving average price of $109.75.
In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the sale, the executive vice president now owns 33,190 shares in the company, valued at approximately $4,181,608.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $120.05, for a total value of $735,066.15. Following the completion of the sale, the executive vice president now owns 41,698 shares in the company, valued at approximately $5,005,844.90. The disclosure for this sale can be found here. Insiders sold a total of 34,332 shares of company stock worth $4,163,091 in the last quarter. Corporate insiders own 0.29% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Glassman Wealth Services lifted its stake in shares of Zoetis by 306.5% in the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock valued at $25,000 after purchasing an additional 190 shares during the period. JJJ Advisors Inc. acquired a new position in shares of Zoetis in the 2nd quarter valued at about $25,000. Prestige Wealth Management Group LLC acquired a new position in shares of Zoetis in the 2nd quarter valued at about $27,000. Altshuler Shaham Ltd lifted its stake in shares of Zoetis by 198.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after purchasing an additional 169 shares during the period. Finally, Next Capital Management LLC lifted its stake in shares of Zoetis by 156.5% in the 2nd quarter. Next Capital Management LLC now owns 295 shares of the company’s stock valued at $33,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 90.09% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.